DY
DY
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
1
$551K
Insider Sales
0
$0
Total Volume
$551K
7 transactions
Net Activity
+$551K
Net buying
Sentiment Rating
Moderate AccumulationCEO Conviction Index
No Recent Signal
Key Drivers
- •Strong buying bias: purchases represent 100% of total transaction value.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
DY has an insider buy conviction of 100%, compared to the Unknown sector buy average of 50%. DY ranks #37 in insider activity out of 247 tracked companies in its industry.
Multiple Insiders
3 Insiders
$551K total
Over the last 90 days, corporate insiders at DY (DY) engaged in a total of 7 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 0 were sales. The total volume of insider trading reached $551K.
The net insider activity for DY shows a net buying bias of $551K. This activity represents a 100% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Purchase by Multiple Insiders (3 Insiders), who traded 1.9K shares valued at $551K on Sep 23, 2026.
Quick Actions
Related News & Analyst Reports
Read original insights and educational research covering DY and the Unknown sector.
The Biotech Executive Playbook: Tracking Clinical Phase SEC Filings
An empirical study on how clinical-stage biotech executives execute Form 4 open-market purchases ahead of trial data releases, outlining the regulatory gaps and alpha potential of clinical insider tracking.
a16z Capital Distributions vs. Open-Market Insider Buying: A 2026 Study
A 2026 empirical study comparing Andreessen Horowitz's in-kind share distributions to LPs against open-market insider purchases, revealing which signal better predicts 12-month price performance.
Insider Trading and Earnings Announcements: Spotting the Catalyst
How does insider trading activity in the 30 days before earnings compare to post-announcement prices? This study quantifies the predictive power of pre-earnings Form 4 purchases after accounting for blackout period compliance.
Venture Spinoffs vs. Direct Listings: A Comparative Analysis of Insider Holding Trends
Venture-backed spinoffs and direct listings both skip traditional IPO underwriting, but their insider holding dynamics differ sharply. This study compares Form 4 patterns at spinoff-versus-direct-listing companies to identify which structure produces stronger alignment signals.
Tracking Insiders in Dow Jones Companies: A 10-Year Study
A decade-long empirical study of Form 4 insider buying activity across all 30 Dow Jones Industrial Average components, analyzing purchase frequency, transaction size, CEO versus director patterns, and 12-month forward performance across different market regimes.
How the Stock Market Reacts to Sudden CEO Resignations and Insider Sells
When a CEO abruptly resigns with a cluster of insider sells immediately following, the market often misses the full picture. This event study tracks 90-day price reactions to sudden leadership changes paired with Form 4 selling activity.
FAQs About DY Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for DY.